Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a ...

Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. As head of oncology, Legos will ...

Pfizer has partnered with Syapse to use the San Francisco-based software company's data-sharing network and insights platform to advance the development of precision cancer treatments.

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.